|
|
|
| Effect of Dapagliflozin on kidney injury in diabetic nephropathy mice through Caspase-1 mediated pyroptosis |
| WANG Ying1 YIN Doudou1 CHAO Nan2 |
1.The First Department of Internal Medicine, Changzhou Medical District, the 904th Hospital of the Joint Logistics Support Force of Chinese People’s Liberation Army, Jiangsu Province, Changzhou 213000, China;
2.Department of Pharmacy, Changzhou Medical District, the 904th Hospital of the Joint Logistics Support Force of Chinese People’s Liberation Army, Jiangsu Province, Changzhou 213000, China
|
|
|
|
Abstract Objective To investigate the effect of Dapagliflozin (DAP) on kidney injury in diabetic nephropathy (DN) mice based on the pyrocytosis mediated by cysteine aspartic acid specific protease-1(Caspase-1) pathway. Methods Thirty SPF grade C57BL/6 male mice, aged eight weeks and weighing 17-25 g, were divided into control group, model group, and DAP group with ten mice in each group according to random number table method. DN model was established in model group and DAP group, and ordinary diet was given to control group. DAP group was given 1 mg/ (kg·d) DAP by intragastric administration, while control group and model group were given the same amount of normal saline by intragastric administration for consecutive four weeks. After drug intervention, the general conditions, serum creatinine, 24 h urinary protein, and serum interleuking-18 (IL-18) levels of each group were compared. Pathological changes of kidney were observed. The expression of Caspase-1 pathway related proteins in mouse kidney was compared. Results Compared with the control group, the model group was listless, less active, occasionally shivering, urine volume was increased significantly, and thinner. Compared with model group, DAP group showed polydipsia and hyperbiosis, and the urine volume was not obvious increased and the activity was normal. Compared with control group, 24 h urinary protein, serum creatinine, serum IL-18 levels and NLR family pyrin domain containing 3 (NLRP3), Caspase-1, GSDMD, and IL-18 protein levels in model group were significantly increased (P＜0.05). Compared with model group, 24 h urinary protein, serum creatinine and serum IL-18 levels, NLRP3, Caspase-1, GSDMD, and IL-18 protein levels in DAP group were significantly decreased (P＜0.05). Conclusion DAP may protect kidney by inhibiting NLRP3/Caspase-1 signaling pathway to activate and inhibit pyrodeath.
|
|
|
|
|
|
[1] 张瑜，姚佳佳，黄莉吉，等.细胞焦亡在糖尿病肾病发病机制中作用的研究进展[J].国际内分泌代谢杂志，2022， 42（2）：150-153，160.
[2] 范慧洁，杨雪，殷璐，等.达格列净联合胰岛素治疗2型糖尿病的效果及其对血糖波动的影响[J].中国实用医刊，2021，48（2）：99-102.
[3] 岳薇薇，阿克拜尔·乌普，王卫群.丹参酮ⅡA磺酸钠联合达格列净对糖尿病大鼠肾损伤的改善作用及其机制研究[J].中南药学，2020，179（12）：32-37.
[4] 赵为陈，沈炳香，何春远，等.GSDMD依赖性细胞焦亡在糖尿病肾病肾脏损伤中的作用机制[J].中国药理学通报，2020，36（7）：964-970.
[5] 吴光秀，夏培金，孙建娟.达格列净对糖尿病肾病患者肾功能和外周血NLRP3炎性小体表达的影响[J].现代中西医结合杂志，2020，29（32）：25-28.
[6] 杨亦彬，张翥，苏克亮，等.链脲佐菌素诱导大鼠糖尿病肾病模型的方法学探讨[J].华西医学，2005，20（2）：299- 300.
[7] 杨琳琳，王玉洁，刘刚，等.N-乙酰半胱氨酸对膜性肾病大鼠肾脏的保护作用[J].实用医学杂志，2019，35（6）：12- 18.
[8] 孙志强.白细胞介素-18和Nephrin在糖尿病肾病大鼠的表达及替米沙坦干预的研究[D].开封：河南大学，2010.
[9] 郑鹏，王俊帅，占大钱，等.丹参酮ⅡA通过NLRP3/Caspase-1信号通路对心肌成纤维细胞的保护作用[J].世界中医药，2021，16（6）：916-919.
[10] 赵为陈，沈炳香，何春远，等.GSDMD依赖性细胞焦亡在糖尿病肾病肾脏损伤中的作用机制[J].中国药理学通报，2020，36（7）：964-970.
[11] 周正维，吴莉莉，唐劲松.探讨尿微量白蛋白/肌酐比值在糖尿病肾病早期诊断中的应用[J].中国实用医药，2019， 14（24）：11-13.
[12] 李素芬，苏彩霞，黄志玲，等.达格列净联合二甲双胍短期强化治疗初诊2型糖尿病患者的临床观察[J].中国医药指南，2020，18（24）：63-69.
[13] 王琴，沈呈，廖静，等.达格列净干预改善糖尿病肾病模型大鼠的肾脏损伤[J].中国组织工程研究，2022，26（8）：1272-1278.
[14] 王美子，岳丽军，万毅刚，等.葛根芩连汤加味方改善糖尿病肾病模型鼠足细胞焦亡和胰岛素抵抗的作用和机制[J].中国中药杂志，2021，46（17）：4471-4479.
[15] 袁小利，王守俊.达格列净对2型糖尿病肾病患者的临床疗效[J].河南医学研究，2020，29（11）：55-57.
[16] 秦莉，张秋菊.达格列净联合利拉鲁肽注射液对糖尿病肾病患者蛋白尿的影响观察[J].中国医药科学，2022， 12（20）：78-81.
[17] 赵为陈，何春远，王法财.以caspase-1介导细胞焦亡筛选治疗糖尿病肾病潜在的中药及单体成分[J].南方医科大学学报，2020，40（9）：1280-1287.
[18] 蒲阅丽，刘淬平，徐勇，等.恩格列净通过抑制细胞焦亡改善糖尿病小鼠肾脏损伤[J].中华内分泌代谢杂志，2021， 37（2）：149-155.
[19] 赵雪杉，安至超，柳红芳，等.芪地糖肾颗粒对糖尿病肾病大鼠模型炎症因子IL-6，IL-18，TNF-α，CRP的影响[J].中国中西医结合肾病杂志，2020，21（1）：8-11.
[20] 周兴艳，李华，柳茜，等.糖尿病小鼠肾组织中细胞焦亡发生的现象研究[J].贵州医科大学学报，2020，45（4）：422-426，431.
[21] 熊哲学，唐明娟，李凝旭.达格列净通过上调SIRT1增强糖尿病肾病大鼠肾脏细胞自噬从而抑制足细胞损伤[J].中国病理生理杂志，2022，38（4）：680-687.
[22] 王彤丹.达格列净对新发2型糖尿病肾脏损伤的保护作用及机制研究[D].天津：天津医科大学，2020.
[23] 徐晓宏，张策，米侠，等.达格列净在2型糖尿病肾病中的应用效果[J].中国当代医药，2022，29（16）：5-10.
[24] 张梓焜.达格列净通过抑制血清/糖皮质激素调节激酶1逆转Th17/Tregs失衡延缓糖尿病肾脏疾病进展[D].广州：南方医科大学，2019. |
|
|
|
